Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Tandem Meetings 2023 | The use of salvage second autologous transplant in the age of novel therapies for multiple myeloma

Michael Slade, MD, Washington University School of Medicine, St Louis, MO, discusses the use of salvage second autologous stem cell transplantation (autoSCT) in the era of novel cellular and antibody-based therapies for multiple myeloma. Dr Slade explains that whilst the use of this treatment is decreasing, several retrospective analyses have shown a benefit for specific subsets of patients and are suggesting that a longer period of time before a second autoSCT could lead to better outcomes. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.